UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

Adverum Biotechnologies, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value

(Title of Class of Securities)

 

00773U207

(CUSIP Number)

 

September 30, 2024

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

1.

NAMES OF REPORTING PERSONS

 

Vivo Opportunity Fund Holdings, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ☐

(b) þ

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

218,895 (1)

6.

SHARED VOTING POWER

 

0

7.

SOLE DISPOSITIVE POWER

 

218,895 (1)

8.

SHARED DISPOSITIVE POWER

 

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

218,895 (1)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

1.1% (2)

12.

TYPE OF REPORTING PERSON

 

PN

 

(1)

The number represents shares of common stock, $0.0001 par value (the “Common Stock”) of Adverum Biotechnologies, Inc. (the “Issuer”) held of record by Vivo Opportunity Fund Holdings, L.P. as of October 31, 2024. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

 

(2)

Based on 20,802,463 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 4, 2024.

 

2

 

 

1.

NAMES OF REPORTING PERSONS

 

Vivo Opportunity, LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ☐

(b) þ

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

218,895 (1)

6.

SHARED VOTING POWER

 

0

7.

SOLE DISPOSITIVE POWER

 

218,895 (1)

8.

SHARED DISPOSITIVE POWER

 

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

218,895 (1)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

1.1% (2)

12.

TYPE OF REPORTING PERSON

 

OO

 

(1)

The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. as of October 31, 2024. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

 

(2)

Based on 20,802,463 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 4, 2024.

 

3

 

 

Item 1. (a) Name of Issuer:

 

Adverum Biotechnologies, Inc. (the “Issuer”)

 

  (b) Address of Issuer’s Principal Executive Offices:

 

100 Cardinal Way, Redwood City, CA 94063 

 

Item 2. (a) Name of Person Filing:

 

(i)Vivo Opportunity Fund Holdings, L.P.

 

(ii)Vivo Opportunity, LLC

 

  (b) Address of Principal Business Office or, if None, Residence:

 

192 Lytton Avenue, Palo Alto, CA 94301

 

  (c) Citizenship:

 

(i)Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and

 

(ii)Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

 

  (d) Title of Class of Securities:

 

Common Stock, $0.0001 par value

 

  (e) CUSIP Number:

 

00773U207

 

Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

 

  (a) Broker or dealer registered under Section 15 of the Act.
       
  (b) Bank as defined in Section 3(a)(6) of the Act.
       
  (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act.
       
  (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940.
       
  (e) ☐  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
       
  (f) ☐  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
       
  (g) ☐  A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
       
  (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
       
  (i) ☐  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
       
  (j) ☐  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
       
  (k) ☐  Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

 

Not Applicable.

 

4

 

 

Item 4. Ownership.

 

  (a) Amount Beneficially Owned:

 

All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

 

  (b) Percent of class:

 

1.1%

 

  (c) Number of shares as to which such person has:

 

  (i) Sole power to vote or to direct the vote:  218,895 shares

 

  (ii) Shared power to vote or to direct the vote: 0

 

  (iii) Sole power to dispose or to direct the disposition of:  218,895 shares

 

  (iv) Shared power to dispose of or to direct the disposition of: 0

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

 

5

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: November 14, 2024

 

Vivo Opportunity Fund Holdings, L.P.

 

By: Vivo Opportunity, LLC, its General Partner  
     
/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  

 

Vivo Opportunity, LLC

 

/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  

 

6

 

 


Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Adverum Biotechnologies.
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Adverum Biotechnologies.